

---

---

**Yung-Chi Cheng, Ph.D.**

Department of Pharmacology, Yale University School of Medicine

333 Cedar Street, PO Box 208066

New Haven, CT 06520-8066, U.S.A.

Phone No.: +1-203-785-7118

Fax No.: +1-203-785-7129

E-mail: [yccheng@yale.edu](mailto:yccheng@yale.edu)

Web: <http://info.med.yale.edu/pharm/faculty/index.php?bioID=6>

---

---

**Education**

- 1966 B.S., Chemistry, Tunghai University, Taiwan  
1972 Ph.D., Biochemical Pharmacology, Brown University, U.S.A.

**Research and Professional Positions Held in Chronological Sequence**

- 1973-1974 Research Assistant Professor, Department of Pharmacology, Yale University School of Medicine, U.S.A.  
1974-1976 Senior Cancer Research Scientist, Department of Experimental Therapeutics, Roswell Park Memorial Institute, U.S.A.  
1974-1977 Assistant Professor, Department of Pharmacology, Roswell Park Division of the Graduate School, State University of New York, U.S.A.  
1976-1977 Associate Cancer Research Scientist, Department of Experimental Therapeutics, Roswell Park Memorial Institute, U.S.A.  
1977-1979 Associate Professor, Department of Pharmacology, Roswell Park Division of the Graduate School, State University of New York, U.S.A.  
1977-1979 Cancer Research Scientist V, Department of Experimental Therapeutics, Roswell Park Memorial Institute, U.S.A.  
1979-1989 Professor, Departments of Pharmacology and Medicine, School of Medicine, University of North Carolina, U.S.A.  
1979-1989 Head, Drug Development Program, Lineberger Cancer Research Center, School of Medicine, University of North Carolina, U.S.A.  
1987 Special Chair, Institute of Biomedical Science, Academia Sinica, Taiwan  
1989-present Professor, Pharmacology and Internal Medicine, Yale University School of Medicine, U.S.A.  
1989-present Henry Bronson Professor of Pharmacology, Yale University School of Medicine, U.S.A.  
1990-2011 Program Director, Developmental Therapeutics/Chemotherapy, Yale Comprehensive Cancer Center, U.S.A.  
Professional Societies: American Association for Cancer Research  
Member of Sigma XI  
American Microbiology Society  
American Society of Pharmacology and Experimental Therapeutics  
American Society of Biological Chemistry  
American Association for the Advancement of Science

American Society for Clinical Pharmacology and Therapeutics  
Society of Chinese Bioscientists in America  
The Protein Society

### **Research Interests**

My interests are in the development of new drugs and the improvement of the use of clinically proven drugs for the treatment of cancer, and herpes virus, human immunodeficiency virus or hepatitis B virus associated diseases. The types of agents are deoxyribonucleoside analogs, folate analogs and compounds that interfere with DNA and RNA metabolism. Currently we are also interested in the potential uses of Chinese medicines. Therefore, we are studying:

1. The metabolism of nucleosides, oligonucleotides, folates and natural products in cell culture;
2. The properties of human or virus nucleoside, folate and DNA metabolizing enzymes;
3. Gene regulation of these enzymes in cells;
4. The behavior of nucleoside analogs, folate analogs, oligonucleotides and DNA metabolic targeting compounds toward these enzymes and cells;
5. The effects of these compounds on virus specific enzymes and virus replication;
6. The action of promising compounds on tumor growth in vivo;
7. The combined use of these agents with other agents, including collaterally sensitive compounds and Chinese medicines, and scheduling the drug for chemotherapy of cancer and virus induced diseases;
8. The mechanisms of drug toxicity, drug resistance and development of drug resistance;
9. The association of human tumors with herpes virus, hepatitis B and retrovirus
10. The biochemical behavior and genetic stability of tumor cells taken from patients.
11. The approaches in bringing Chinese Medicine into the mainstream of new medicine in the 21<sup>st</sup> century.
12. Discovery of anti-HIV, HBV and HCV chemicals with selectivity by targeting viral proteins.

There are over 450 publications in Refereed Journals. There are four approved drugs currently used in clinic. These includes: Gancyclovir, Lamivudine, Clevudine, and Emtricitabine. In addition, three chemicals discovered in this lab and one Chinese medicine formula were discovered and are currently at different stages of Clinical Trial for the treatment of cancer as well as HIV and HBV infection.

### **Major Honors and Awards**

- |           |  |
|-----------|--|
| 1976-1981 | American Leukemia Society Scholar  |
| 1981      | Rhoads Memorial Award, American Association of Cancer Research           |
| 1987-1997 | Outstanding Investigator Award, National Cancer Institute, U.S.A.        |
| 1990      | Outstanding Alumni Award, Brown University, U.S.A.                       |
| 1991      | Honorary Professor, Beijing Medical University, China                    |
| 1992      | Honorary Professor, Union Medical University and CAMS, China             |
| 1992      | Outstanding Award in Bio-Medical Science, SCBA                           |
| 1994      | Academician, Academia Sinica, Taiwan                                     |
| 1998      | Honorary Vis Sci, Institute of the Advancement of Chinese Medicine, Hong |

	Kong Chinese University
1998	Academician, Connecticut Academy of Science and Engineering, U.S.A.
1999	ASPET Award (American Society For Pharmacology and Experimental Therapeutics)
1999	Honorary Professor, Harbin Medical University, China
2000-present	National Foundation for Cancer Research Fellow
2001	Distinguished Alumni Award, Tunghai University, Taiwan
2001	Honorable Professor, Zhejiang University, Hangzhou, China
2002	Outstanding Achievement Award, Chinese/American Acad Prof Soc
2002	Honorable Professor, School of Medicine, University of Hong Kong
2003	Honorary Professor, Institute of Materia Medica, Chinese Academy of Science
2004	Presidential Award, Society of Chinese Bioscientists in America
2005	BMRC Distinguished Visitor, Singapore
2005	Distinguished Visiting Professor, The University of Hong Kong
2007	Honorary Chair Professor, Chinese Medical University, Taiwan
2008	Honorary Professor, Xiamen University
2008	Honorary Professor, Yunan Medical College
2011	Honorary Professor Shanghai Chinese Medicine University
2011	Honorary Professor Heilongjiang University of Chinese Medicine
2012	Cheung on Tak International Award for Outstanding Contributions to Chinese Med

#### Extramural Committees Served

##### Business:

1981-1988	Consultant, Antivirus Program, Syntex Inc.
1981-1986	Member, Scientific Advisory Board, G.D. Pharmaceutical Co
1985	Member, Burroughs-Wellcome Fund Task Force, NC
1986-1991	Consultant, Antivirus Program, Bristol-Myers, Inc.
1987	President, Society of Chinese Bioscientists in America
1988-1994	Consultant, Antivirals, Wyeth-Ayerst Laboratories
1988-1998	Consultant, Scientific Advisory Board, Genelabs, Inc.
1989-1993	Consultant, DuPont Pharmaceuticals
1990-1994	Consultant, Boehringer Ingelheim Pharmaceuticals
1990-1994	Consultant, Boehringer Ingelheim Pharmaceuticals
1990-1998	Member and Co-Chairman, Scientific Advisory Board, Sparta Pharmaceuticals
1991-1994	Member, Scientific Advisory Board, Genelabs, Inc.
1991-1994	Member, Scientific Advisory Board, MicroProbe, Inc.
1991-1996	Member, Scientific Advisory Board, HEM Pharmaceuticals
1991-1998	Member, Scientific Advisory Board, U.S. Bioscience
1994-1997	Chairman of the Board, Division of Bio/Pharm, SCBA
1995-2007	Member, Scientific Advisory Board, Vion Pharmaceutical
1996-2002	Consultant, Biochem Pharma

- 1997-2000 Director, Board of Directors, Response Biomedical Board, Vancouver, B.C
- 1998-2000 Member, Scientific Advisory Board, Triangle Pharmaceuticals
- 1999-2000 Consultant in Chinese Medicine, New World Development, HK
- 1999-Present Scientific Founder/Chairman, Scientific Advisory Board, Phytoceutica
- 2000-2003 Consultant, Triangle Pharmaceuticals
- 2000-2006 Scientific Founder/Chairman, Scientific Advisory Board, Achillion
- 2006-Present Chairman, Consortium for the “Globalization of Chinese Medicine” (CGCM)
- 2006-Present Member, Sci Adv Bd, FINOVI “Foundation Innovations en Infectiologie”
- 2007-Present Consultant, Oncolys BioPharma, Inc.

#### Academic and Government:

- 1980-1984 Member, Study Section of Experimental Therapeutics, NIH
- 1983-1984 Chairman, Study Section of Experimental Therapeutics, NCI/ NIH
- 1984 Chairman, Gordon Research Conf "Purines, Pyrimidines, and Related Compounds
- 1986-1990 Member, Board of Scientific Counselors, Division of Cancer Treatment, NCI/NIH
- 1984-1986 Member, External Advisory Board of Wisconsin Clinical Cancer Center, Madison
- 1987 President, Society of Chinese Bioscientists in America
- 1987 Chairman, Biochemistry Section, Annual Meeting of the AACR
- 1988 Chairman, AACR Clowes Award Subcommittee
- 1991-1994 Member, AIDS Research Advisory Committee, NIAID, NIH
- 1994-1997 Chairman, Study Section of the Biopharmaceutical Science, NHRI
- 1994-1997 Chairman of the Board, Bio/Pharm Division SCBA
- 1995–Present Member, Board of Scientific Counselors, National Health Research Institute, Taiwan
- 1996-1999 Chairman, Action Committee for Med. Biotech., Academia Sinica
- 1996-2000 Special Advisor to the Committee for the Biotechnology Industry Under Executive Yuan, Taiwan
- 1996-2003 Panel Member of Biomedical Science. University Grant Committee, Hong Kong
- 1999 Consultant, The Hong Kong University of Science & Technology
- 1999-2001 Chairman, Advisory Committee for Med. Biotech. Academia Sinica
- 1999-2004 Chairman, International Advisory Board for Bio/Pharm Division (SCBA) Sponsored Herbal Medicine Symposium (1) Toronto, 1997); (2) Hong Kong, 1998; (3) Taiwan, 2000; and (4) Shanghai, 2004.
- 2001-present Member Scientific Advisory Board – Beijing Nat’l Biochip Research and Engineering Center
- 2002-Present Chairman, Steering committee for program of Chinese Medicine, Hong Kong University

- 2002-Present Chief Consultant, Program of Chinese Medicine, Shanghai Institute of Life Sciences, Chinese Academy of Science
- 2003-Present Chief Consultant, Program of Chinese Medicine, Chinese Acad Med Sci (CAMS)
- 2003-Present Chairman, Consortium for “Globalization of Chinese Medicine” (CGCM)
- 2005-2008 Ad hoc Member, National Advisory Council for (NCAM/NIH), U.S.A.
- 2007-present Chief Consultant and Advisor for Biotech/Pharm, Yunnan Province
- 2008-present Chairman, Sci Adv Bd, Agriculture Biotech Ctr, Academia Sinica
- 2008-present Member, Sci Adv Bd, FINOVI Foundation Innovations en Infectiologie
- 2009-present Member, International Advisory Board TCM Research Center, Graz, Austria
- 2010-present Co-Chairman, Advisory Board GP-TCM Advisory Board, London, UK

Editorial Boards:

- 1983-1986 Associate Editor, Methotrexate Update, Lederle Laboratories
- 1987-Present Editorial Board, Virus Genes, Martinus Nijhoff Publishing
- 1989-Present Editorial Board, Cancer Communications, Pergamon Press
- 1990-1995 Associate Editor, Cancer Research, Waverly Press
- 1990-2003 Associate Editor, Biochemical Pharmacology, Pergamon Press
- 1995-Present Advisory Board, J. Biomedical Science, Kerger Press
- 1995-Present Advisory Board, Chinese Journal of Pharmacology & Toxicology

